Abivax

EnterNext welcomes Abivax on Euronext in Paris

Professor Hartmut Ehrlich, CEO of Abivax, rings the closing bell.

Abivax specializes in the research, development and commercialization of anti-viral drugs and therapeutic vaccines for the treatment of severe infectious diseases.
At the end of 2014, the Group has a portfolio of three products in clinical development: ABX203 (therapeutic vaccine against chronic hepatitis B), ABX464 (new drug against HIV) and ABX196 (adjuvant vaccine against hepatitis B).